Strontium should no longer be used for osteoporosis … - IdmcrackfreedownloadInfo

Strontium should no longer be used for osteoporosis …

By continuing to browse or by clicking “Accept All Cookies,” you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Find out more .

Cookie Settings

You might also like…
×
New guidance for treatment of bone loss in hematologic stem cell transplant Recipients

Skip to Main Content
Working...

ClinicalTrials.gov


ClinicalTrials.gov Menu

×

  • Find StudiesFind Studies Menu
    • New Search
    • Advanced Search
    • See Studies by Topic
    • See Studies on Map
    • How to Search
    • How to Use Search Results
    • How to Find Results of Studies
    • How to Read a Study Record
  • About StudiesAbout Studies Menu
    • Learn About Studies
    • Other Sites About Studies
    • Glossary of Common Site Terms
  • Submit StudiesSubmit Studies Menu
    • Why Should I Register and Submit Results?
    • FDAAA 801 and the Final Rule
    • How to Apply for an Account
    • How to Register Your Study
    • How to Edit Your Study Record
    • How to Submit Your Results
    • Frequently Asked Questions
    • Support Materials
    • Training Materials
  • ResourcesResources Menu
    • Selected Publications
    • Clinical Alerts and Advisories
    • RSS Feeds
    • Trends, Charts, and Maps
    • Downloading Content for Analysis
  • About SiteAbout Site Menu
    • What’s New
    • ClinicalTrials.gov Background
    • About the Results Database
    • History, Policies, and Laws
    • Media/Press Resources
    • Linking to This Site
    • Terms and Conditions
    • Disclaimer

  • Find StudiesFind Studies Menu
    • New Search
    • Advanced Search
    • See Studies by Topic
    • See Studies on Map
    • How to Search
    • How to Use Search Results
    • How to Find Results of Studies
    • How to Read a Study Record
  • About StudiesAbout Studies Menu
    • Learn About Studies
    • Other Sites About Studies
    • Glossary of Common Site Terms
  • Submit StudiesSubmit Studies Menu
    • Why Should I Register and Submit Results?
    • FDAAA 801 and the Final Rule
    • How to Apply for an Account
    • How to Register Your Study
    • How to Edit Your Study Record
    • How to Submit Your Results
    • Frequently Asked Questions
    • Support Materials
    • Training Materials
  • ResourcesResources Menu
    • Selected Publications
    • Clinical Alerts and Advisories
    • RSS Feeds
    • Trends, Charts, and Maps
    • Downloading Content for Analysis
  • About SiteAbout Site Menu
    • What’s New
    • ClinicalTrials.gov Background
    • About the Results Database
    • History, Policies, and Laws
    • Media/Press Resources
    • Linking to This Site
    • Terms and Conditions
    • Disclaimer

  • Home
  • Search Results
  • Study Record Detail

Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01544894
Recruitment Status :
Completed

First Posted : March 6, 2012
Last Update Posted : September 3, 2012

Sponsor:
University of Valencia
Information provided by (Responsible Party):
Antonio Cano Sanchez, University of Valencia

  • Study Details
  • Tabular View
  • No Results Posted
  • Disclaimer
  • How to Read a Study Record
Study Description
Go to 

Top of Page
Study Description
Study Design

Arms and Interventions

Outcome Measures
Eligibility Criteria
Contacts and Locations
More Information

Brief Summary:
The purpose of this study was to compare compliance and efficacy of raloxifene and strontium ranelate in a group of women with postmenopausal osteoporosis.

Condition or disease Intervention/treatment Phase
Postmenopausal Osteoporosis
Compliance
Drug: Raloxifene
Drug: Strontium ranelate
Phase 4

Detailed Description:

OBJECTIVE: To compare the performance of raloxifene and strontium rannelate in the management of women with postmenopausal osteoporosis.

DESIGN: Prospective, open label study. SETTING: University hospital menopause unit. PATIENTS: 80 women with postmenopausal osteoporosis were assigned to either raloxifene (60 mg/d) or strontium ranelate (2g/d). Participants were followed for 1 year.

MAIN OUTCOME MEASURE(S): Compliance with each regime. Secondary objectives were parameters of efficacy, including changes in bone mineral density and bone biochemical markers.

Study Design
Go to 

Top of Page
Study Description
Study Design

Arms and Interventions

Outcome Measures
Eligibility Criteria
Contacts and Locations
More Information

Study Type : Interventional
 (Clinical Trial)

Actual
Enrollment :
80 participants
Allocation:Non-Randomized
Intervention Model:Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title:Comparison of Raloxifene and Strontium Ranelate on Compliance and Efficacy in Women With Postmenopausal Osteoporosis
Study Start Date :September 2009
Actual Primary Completion Date :October 2011
Actual Study Completion Date :October 2011
Resource links provided by the National Library of Medicine

MedlinePlus related topics:
Osteoporosis
Drug Information available for:
Raloxifene
U.S. FDA Resources

Arms and Interventions
Go to 

Top of Page
Study Description
Study Design

Arms and Interventions

Outcome Measures
Eligibility Criteria
Contacts and Locations
More Information

Arm Intervention/treatment
Active Comparator: raloxifene

60 mg/d for one year.
Drug: Raloxifene

60 mg/d for one year
Other Name: Evista

Active Comparator: strontium ranelate

2 g/d for one year.
Drug: Strontium ranelate

2 g/d, for one year
Other Name: Protelos

Outcome Measures
Go to 

Top of Page
Study Description
Study Design

Arms and Interventions

Outcome Measures
Eligibility Criteria
Contacts and Locations
More Information

Primary Outcome Measures :

  1. Clinical study of raloxifene and strontium ranelate in postmenopausal osteoporosis [ Time Frame: One year ]
    Primary Outcome measure: compliance. Assessment of compliance assessed two variables, the number of participants maintaining treatment after one year and, among those that completed the one year treatment, the number of them that completed at least 80% of the prescribed dose.

Secondary Outcome Measures :

  1. Clinical study of raloxifene and strontium ranelate in postmenopausal osteoporosis [ Time Frame: One year ]

    Secondary outcome measure: efficacy. Efficacy has been assessed by changes in axial bone mineral density (spine and hip) and by changes in biochemical bone markers (C-telopeptides and P1NP in serum).

    Axial densitometry has been performed prior to treatment and after completion of the programmed one-year treatment.

    Bone markers have been assessed prior to treatment and at the 3rd, 6th and 12th month of treatment.

Eligibility Criteria
Go to 

Top of Page
Study Description
Study Design

Arms and Interventions

Outcome Measures
Eligibility Criteria
Contacts and Locations
More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Postmenopausal women with densitometric osteoporosis

Exclusion Criteria:

  • Secondary osteoporosis

Contacts and Locations
Go to 

Top of Page
Study Description
Study Design

Arms and Interventions

Outcome Measures
Eligibility Criteria
Contacts and Locations
More Information

Information from the National Library of Medicine


To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.


Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01544894

Locations
Spain
Hospital Universitario Dr Peset
Valencia, Spain, 46017
Sponsors and Collaborators
University of Valencia
Investigators
Study Director:Antonio Cano, MDUniversity of Valencia
More Information
Go to 

Top of Page
Study Description
Study Design

Arms and Interventions

Outcome Measures
Eligibility Criteria
Contacts and Locations
More Information

Responsible Party:Antonio Cano Sanchez, Professor in Obstetrics and Gynecology, University of Valencia
ClinicalTrials.gov Identifier: NCT01544894    
History of Changes
Other Study ID Numbers: Sr-ral-postmOTP
First Posted:March 6, 2012
  
Key Record Dates
Last Update Posted:September 3, 2012
Last Verified:August 2012

Keywords provided by Antonio Cano Sanchez, University of Valencia:

Postmenopausal osteoporosis
Compliance
Bone mineral density
Bonemarkers

Additional relevant MeSH terms:

Osteoporosis
Osteoporosis, Postmenopausal
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Raloxifene Hydrochloride
Strontium ranelate
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Bone Density Conservation Agents
To Top

  • For Patients and Families
  • For Researchers
  • For Study Record Managers
  • Home
  • RSS Feeds
  • Site Map
  • Terms and Conditions
  • Disclaimer
  • Customer Support
  • Copyright
  • Privacy
  • Accessibility
  • Viewers and Players
  • Freedom of Information Act
  • USA.gov
  • U.S. National Library of Medicine
  • U.S. National Institutes of Health
  • U.S. Department of Health and Human Services


Mayo Clinic Connect

  • Home
  • Discuss
    • Groups
    • Pages
    • Members
  • Learn
    • Video QA
    • Calendar
  • ESPAÑOL
  • Champions
    • Champions Corner
    • Leaderboard

  1. Groups
  2. Bones, Joints & Muscles
  3. Osteoporosis treatment or strontium citrate?
Share this:
 
 
 
 
 

bonelady
@bonelady
Posts: 3
Joined: May 10, 2018

Osteoporosis treatment or strontium citrate?

Posted by @bonelady , Thu, May 10 7:01am

Is reclast a safe treatment for osteoporosis I have not done anything so far except strontium citrate

REPLY

    Follow

Reported

bonelady
@bonelady

Posts: 3
Joined: May 10, 2018

Posted by bonelady @bonelady , Thu, May 10, 2018 7:04am

I have osteoporosis and am afraid of the treatments for it have been trying strontium citrate not sure about my decision.

Liked by bonelady

bonelady
@bonelady

Posts: 3
Joined: May 10, 2018

Posted by bonelady @bonelady , Thu, May 17, 2018 9:10pm

am in the same situation, I wish someone from mayo could give a good answer to us…

MENTOR

John, Volunteer Mentor
@johnbishop

Posts: 2835
Joined: Mar 22, 2016

Posted by John, Volunteer Mentor @johnbishop , Fri, May 18, 2018 7:12am

Hello @bonelady — welcome to Connect. I’m glad you found us. I was diagnosed with osteopenia a little over a year ago but have not done anything other than trying to add more calcium rich food to my diet. I did find some information on the Mayo Clinic website on osteoporosis.

Osteoporosis treatment: Medications can help — Osteoporosis treatment may involve medication along with lifestyle change. Get answers to some of the most common questions about osteoporosis treatment.
— https://www.mayoclinic.org/diseases-conditions/osteoporosis/in-depth/osteoporosis-treatment/art-20046869

Have you discussed any treatments with your doctor or have they recommended anything to you?

John

Liked by Teresa, Volunteer Mentor

MODERATOR

Justin McClanahan
@JustinMcClanahan

Posts: 1097
Joined: Jun 01, 2016

Posted by Justin McClanahan @JustinMcClanahan , Fri, May 18, 2018 9:46am

Hello @bonelady . @faith123 , recently posted about having a second reclast infusion recently here, https://connect.mayoclinic.org/discussion/reclast-infusion/ . Faith123 may be able to answer a question or two of yours about the reclast infusion treatment and her experience with it.

Liked by John, Volunteer Mentor

bonnieh218
@bonnieh218

Posts: 76
Joined: Feb 15, 2017

Posted by bonnieh218 @bonnieh218 , Fri, May 18, 2018 10:39am
In reply to @JustinMcClanahan “Hello @bonelady. @faith123, recently posted about having a second reclast infusion recently…” + (show) (hide)

@JustinMcClanahan

Hello @bonelady . @faith123 , recently posted about having a second reclast infusion recently here, https://connect.mayoclinic.org/discussion/reclast-infusion/ . Faith123 may be able to answer a question or two of yours about the reclast infusion treatment and her experience with it.

Jump to this post

https://americanbonehealth.org/bonesense/why-strontium-is-not-good-for-bone-health/

I just read this article about strontium.
I have had reclast infusions for six years for osteoporosis. I am fortunate to have no noticeable side effects. My bone density has shown some improvement and no further decline. Two years ago I was put on “vacation” from the reclast and haven’t received any further infusions. Mayo docs say it will stay in my system for up to three years. In the mean time I do have bone density scans to keep an eye on bone density. Next year will be my third year off the reclast so it will be interesting to see what docs will then suggest.

Liked by John, Volunteer Mentor

kishanvasekar
@kishanvasekar

Posts: 41
Joined: Feb 21, 2015

Posted by kishanvasekar @kishanvasekar , Fri, May 18, 2018 9:55pm
In reply to @johnbishop “Hello @bonelady — welcome to Connect. I’m glad you found us. I…” + (show) (hide)

@johnbishop

Hello @bonelady — welcome to Connect. I’m glad you found us. I was diagnosed with osteopenia a little over a year ago but have not done anything other than trying to add more calcium rich food to my diet. I did find some information on the Mayo Clinic website on osteoporosis.

Osteoporosis treatment: Medications can help — Osteoporosis treatment may involve medication along with lifestyle change. Get answers to some of the most common questions about osteoporosis treatment.
— https://www.mayoclinic.org/diseases-conditions/osteoporosis/in-depth/osteoporosis-treatment/art-20046869

Have you discussed any treatments with your doctor or have they recommended anything to you?

John

Jump to this post

My wife has severe Osteoporosis .It has been improving with Medicines, Yearly injections , Exercise , Yoga .I think she is more benefitted by Walking in Sunlight abundunly available in India.Some resercah has been done by Ray Vio for Improving VitD UUsing LED lights of 293 nm wavelength.This will help .If Somebody has experience , pl share your experience.Thanks

Please login or register to post a reply.

version 3.3.6.9.6
Page loaded in 0.456 seconds

About the Author: admin